Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $2.5 million.

  • Lyell Immunopharma's Other Non-Current Assets rose 78368.06% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 78368.06%. This contributed to the annual value of $4.6 million for FY2024, which is 913.81% up from last year.
  • Per Lyell Immunopharma's latest filing, its Other Non-Current Assets stood at $2.5 million for Q3 2025, which was up 78368.06% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Non-Current Assets ranged from a high of $4.6 million in Q4 2024 and a low of $279000.0 during Q1 2022
  • Its 5-year average for Other Non-Current Assets is $1.1 million, with a median of $288000.0 in 2024.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first crashed by 4012.88% in 2022, then skyrocketed by 141250.0% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Other Non-Current Assets (Quarter) stood at $466000.0 in 2021, then plummeted by 39.91% to $280000.0 in 2022, then soared by 1412.5% to $4.2 million in 2023, then increased by 9.14% to $4.6 million in 2024, then crashed by 44.94% to $2.5 million in 2025.
  • Its Other Non-Current Assets was $2.5 million in Q3 2025, compared to $2.5 million in Q2 2025 and $3.2 million in Q1 2025.